GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (OTCPK:PTCHF) » Definitions » Price-to-Free-Cash-Flow

PureTech Health (PureTech Health) Price-to-Free-Cash-Flow : N/A (As of May. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Price-to-Free-Cash-Flow?

As of today (2024-05-22), PureTech Health's share price is $2.85. PureTech Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.38. Hence, PureTech Health's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for PureTech Health's Price-to-Free-Cash-Flow or its related term are showing as below:

PTCHF's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.97
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

PureTech Health's Free Cash Flow per Share for the six months ended in Dec. 2023 was $-0.15. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.38.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 4.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -10.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -29.70% per year.

During the past 12 years, PureTech Health's highest 3-Year average Free Cash Flow per Share Growth Rate was 4.50% per year. The lowest was -146.60% per year. And the median was -22.90% per year.


PureTech Health Price-to-Free-Cash-Flow Historical Data

The historical data trend for PureTech Health's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Price-to-Free-Cash-Flow Chart

PureTech Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PureTech Health Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PureTech Health's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, PureTech Health's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PureTech Health's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where PureTech Health's Price-to-Free-Cash-Flow falls into.



PureTech Health Price-to-Free-Cash-Flow Calculation

PureTech Health's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.85/-0.383
=N/A

PureTech Health's Share Price of today is $2.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.38.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

PureTech Health  (OTCPK:PTCHF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


PureTech Health Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of PureTech Health's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


PureTech Health (PureTech Health) Business Description

Traded in Other Exchanges
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.